Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum (Q41862911)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2006

Language	Label	Description	Also known as
English	Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum	scientific article published on March 2006

Statements

scholarly article

1 reference

Europe PubMed Central

13 October 2017

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum (English)

1 reference

Europe PubMed Central

13 October 2017

2

1 reference

Europe PubMed Central

13 October 2017

6

1 reference

Europe PubMed Central

13 October 2017

11

1 reference

Europe PubMed Central

13 October 2017

10

object named as

Hartwig Huland

1 reference

Europe PubMed Central

13 October 2017

Michael W Kattan

7

object named as

Michael W Kattan

1 reference

Europe PubMed Central

13 October 2017

James A Eastham

8

object named as

James A Eastham

1 reference

Europe PubMed Central

13 October 2017

author name string

Thomas Steuber

1

1 reference

Europe PubMed Central

13 October 2017

Alexander Haese

3

1 reference

Europe PubMed Central

13 October 2017

Charlotte Becker

4

1 reference

Europe PubMed Central

13 October 2017

Kim Pettersson

5

1 reference

Europe PubMed Central

13 October 2017

Peter T Scardino

9

1 reference

Europe PubMed Central

13 October 2017

language of work or name

0 references

publication date

1 March 2006

1 reference

Europe PubMed Central

13 October 2017

International Journal of Cancer

1 reference

Europe PubMed Central

13 October 2017

118

1 reference

Europe PubMed Central

13 October 2017

1234-1240

1 reference

Europe PubMed Central

13 October 2017

5

1 reference

Europe PubMed Central

13 October 2017

Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

5 June 2018

Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

5 June 2018

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

5 June 2018

Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

5 June 2018

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

5 June 2018

Results of radical prostatectomy in men with clinically localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

5 June 2018

Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

5 June 2018

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

Development of sensitive immunoassays for free and total human glandular kallikrein 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

Cancer control with radical prostatectomy alone in 1,000 consecutive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950472

18 August 2018

Results of radical prostatectomy in men with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.21474

21 January 2018

International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Testing in Serum for Human Glandular Kallikrein 2, and Free and Total Prostate Specific Antigen in Biannual Screening for Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Total and Gleason Grade 4/5 Cancer Volumes are Major Contributors of Human Kallikrein 2, Whereas Free Prostate Specific Antigen is Largely Contributed by Benign Gland Volume in Serum From Patients With Prostate Cancer or Benign Prostatic Biopsies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml

1 reference

https://pubmed.ncbi.nlm.nih.gov/16152616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/IJC.21474

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41862911&oldid=1928968147"